Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: PREVAIL: A MULTINATIONAL PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ORAL MDV3100 IN CHEMOTHERAPY-NAÏVE PATIENTS WITH PROGRESSIVE METASTATIC PROSTATE CANCER WHO HAVE FAILED ANDROGEN DEPRIVATION THERAPY
Brief Summary: The purpose of this study is to determine the benefit of enzalutamide versus placebo as assessed by overall survival and progression-free survival in patients with progressive metastatic prostate cancer who have failed androgen deprivation therapy but not yet received chemotherapy.


Options:
A: Arm Label: Abiraterone acetate + Prednisone + ADT; Type: EXPERIMENTAL; Interventions: Drug: Abiraterone acetate, Drug: Prednisone, Other: Androgen deprivation therapy (ADT) | Arm Label: Placebo + Androgen Deprivation Therapy (ADT); Type: PLACEBO_COMPARATOR; Interventions: Other: Androgen deprivation therapy (ADT), Drug: Abiraterone acetate Placebo, Drug: Prednisone Placebo | Intervention Type: DRUG; Name: Abiraterone acetate; Assigned to Arm(s): Abiraterone acetate + Prednisone + ADT | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Abiraterone acetate + Prednisone + ADT | Intervention Type: OTHER; Name: Androgen deprivation therapy (ADT); Assigned to Arm(s): Abiraterone acetate + Prednisone + ADT, Placebo + Androgen Deprivation Therapy (ADT) | Intervention Type: DRUG; Name: Abiraterone acetate Placebo; Assigned to Arm(s): Placebo + Androgen Deprivation Therapy (ADT) | Intervention Type: DRUG; Name: Prednisone Placebo; Assigned to Arm(s): Placebo + Androgen Deprivation Therapy (ADT)
B: Arm Label: Enzalutamide; Type: EXPERIMENTAL; Interventions: Drug: Enzalutamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Enzalutamide; Assigned to Arm(s): Enzalutamide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: APC-Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: APC-Placebo | Arm Label: Sipuleucel-T; Type: ACTIVE_COMPARATOR; Interventions: Biological: Sipuleucel-T | Intervention Type: BIOLOGICAL; Name: Sipuleucel-T; Assigned to Arm(s): Sipuleucel-T | Intervention Type: BIOLOGICAL; Name: APC-Placebo; Assigned to Arm(s): APC-Placebo
D: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Other: Androgen Deprivation Therapy, Drug: Docetaxel | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Drug: abiraterone acetate, Other: Androgen Deprivation Therapy, Drug: Docetaxel | Arm Label: Arm C; Type: EXPERIMENTAL; Interventions: Radiation: radiotherapy, Other: Androgen Deprivation Therapy, Drug: Docetaxel | Arm Label: Arm D; Type: EXPERIMENTAL; Interventions: Drug: abiraterone acetate, Radiation: radiotherapy, Other: Androgen Deprivation Therapy, Drug: Docetaxel | Intervention Type: DRUG; Name: abiraterone acetate; Assigned to Arm(s): Arm B, Arm D | Intervention Type: RADIATION; Name: radiotherapy; Assigned to Arm(s): Arm C, Arm D | Intervention Type: OTHER; Name: Androgen Deprivation Therapy; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm A, Arm B, Arm C, Arm D

Answer: B